[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2003022991A3 - Compositions and methods of use of targeting peptides against placenta and adipose tissues - Google Patents

Compositions and methods of use of targeting peptides against placenta and adipose tissues Download PDF

Info

Publication number
WO2003022991A3
WO2003022991A3 PCT/US2002/027836 US0227836W WO03022991A3 WO 2003022991 A3 WO2003022991 A3 WO 2003022991A3 US 0227836 W US0227836 W US 0227836W WO 03022991 A3 WO03022991 A3 WO 03022991A3
Authority
WO
WIPO (PCT)
Prior art keywords
placenta
targeting peptides
adipose
methods
targeting
Prior art date
Application number
PCT/US2002/027836
Other languages
French (fr)
Other versions
WO2003022991A2 (en
Inventor
Renata Pasqualini
Wadih Arap
Mikhail G Kolonin
Original Assignee
Univ Texas
Renata Pasqualini
Wadih Arap
Mikhail G Kolonin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2001/027692 external-priority patent/WO2002020769A1/en
Application filed by Univ Texas, Renata Pasqualini, Wadih Arap, Mikhail G Kolonin filed Critical Univ Texas
Priority to US10/489,071 priority Critical patent/US7452964B2/en
Priority to AU2002323543A priority patent/AU2002323543A1/en
Priority to CA002458047A priority patent/CA2458047A1/en
Priority to EP02757531A priority patent/EP1497314A4/en
Priority to US10/530,168 priority patent/US7671010B2/en
Priority to CA002496938A priority patent/CA2496938A1/en
Priority to EP02799873A priority patent/EP1546714A4/en
Priority to PCT/US2002/034987 priority patent/WO2004020999A1/en
Priority to AU2002364501A priority patent/AU2002364501A1/en
Publication of WO2003022991A2 publication Critical patent/WO2003022991A2/en
Priority to US10/784,537 priority patent/US7420030B2/en
Publication of WO2003022991A3 publication Critical patent/WO2003022991A3/en
Priority to US12/186,208 priority patent/US7914780B1/en
Priority to US12/242,427 priority patent/US7951362B2/en
Priority to US13/084,328 priority patent/US8252764B2/en
Priority to US13/559,222 priority patent/US8846859B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/28—Gramicidins A, B, D; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Child & Adolescent Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention concerns compositions comprising and methods of identification and use of targeting peptides for placenta or adipose tissue. In certain embodiments, the targeting peptides comprise part or all of SEQ ID NO:5-11, SEQ ID NO:13-22 OR SEQ ID NO:144. The peptides may be attached to various therapeutic agents for targeted delivery. Adipose-targeting peptides may be used in methods for weight control, inducing weight loss and treating lipodystrophy syndrome. Adipose-targeting may also be accomplished using other binding moieties selectively targeted to adipose receptors, such as a prohibitin receptor protein complex. Placenta-targeting peptides may be used to interfere with pregnancy, induce labor and/or for targeted delivery of therapeutic agents to placenta and/or fetus. In other embodiments, receptors identified by binding to placenta-targeting peptides may be used to screen compounds for potential teratogenicity. An exemplary placental receptor is FcRn/β2M, and compounds that bind to FcRn/β2M are potential teratogens.
PCT/US2002/027836 2000-09-08 2002-08-30 Compositions and methods of use of targeting peptides against placenta and adipose tissues WO2003022991A2 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
US10/489,071 US7452964B2 (en) 2001-09-07 2002-08-30 Compositions and methods of use of targeting peptides against placenta and adipose tissues
AU2002323543A AU2002323543A1 (en) 2001-09-07 2002-08-30 Compositions and methods of use of targeting peptides against placenta and adipose tissues
CA002458047A CA2458047A1 (en) 2001-09-07 2002-08-30 Compositions and methods of use of targeting peptides against placenta and adipose tissues
EP02757531A EP1497314A4 (en) 2001-09-07 2002-08-30 Compositions and methods of use of targeting peptides against placenta and adipose tissues
AU2002364501A AU2002364501A1 (en) 2002-08-30 2002-10-30 Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
EP02799873A EP1546714A4 (en) 2002-08-30 2002-10-30 Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
CA002496938A CA2496938A1 (en) 2002-08-30 2002-10-30 Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US10/530,168 US7671010B2 (en) 2002-08-30 2002-10-30 Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
PCT/US2002/034987 WO2004020999A1 (en) 2002-08-30 2002-10-30 Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US10/784,537 US7420030B2 (en) 2000-09-08 2004-02-23 Aminopeptidase A (APA) targeting peptides for the treatment of cancer
US12/186,208 US7914780B1 (en) 2000-09-08 2008-08-05 Aminopeptidase A (APA) targeting peptides for the treatment of cancer
US12/242,427 US7951362B2 (en) 2000-09-08 2008-09-30 Compositions and methods of use of targeting peptides against placenta and adipose tissues
US13/084,328 US8252764B2 (en) 2000-09-08 2011-04-11 Compositions and methods of use of targeting peptides against placenta and adipose tissues
US13/559,222 US8846859B2 (en) 2000-09-08 2012-07-26 Compositions and methods of use of targeting peptides against placenta and adipose tissues

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2001/027692 WO2002020769A1 (en) 2000-09-08 2001-09-07 Human and mouse targeting peptides identified by phage display
USPCT/US01/27692 2001-09-07

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/027692 Continuation-In-Part WO2002020769A1 (en) 2000-09-08 2001-09-07 Human and mouse targeting peptides identified by phage display

Related Child Applications (5)

Application Number Title Priority Date Filing Date
US10/489,071 A-371-Of-International US7452964B2 (en) 2000-09-08 2002-08-30 Compositions and methods of use of targeting peptides against placenta and adipose tissues
US10489071 A-371-Of-International 2002-08-30
US10/784,537 Continuation-In-Part US7420030B2 (en) 2000-09-08 2004-02-23 Aminopeptidase A (APA) targeting peptides for the treatment of cancer
US10/784,537 Continuation US7420030B2 (en) 2000-09-08 2004-02-23 Aminopeptidase A (APA) targeting peptides for the treatment of cancer
US12/242,427 Division US7951362B2 (en) 2000-09-08 2008-09-30 Compositions and methods of use of targeting peptides against placenta and adipose tissues

Publications (2)

Publication Number Publication Date
WO2003022991A2 WO2003022991A2 (en) 2003-03-20
WO2003022991A3 true WO2003022991A3 (en) 2004-10-28

Family

ID=21742817

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/027836 WO2003022991A2 (en) 2000-09-08 2002-08-30 Compositions and methods of use of targeting peptides against placenta and adipose tissues

Country Status (4)

Country Link
EP (1) EP1497314A4 (en)
AU (1) AU2002323543A1 (en)
CA (1) CA2458047A1 (en)
WO (1) WO2003022991A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7452964B2 (en) 2001-09-07 2008-11-18 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides against placenta and adipose tissues
US20040170955A1 (en) 2000-09-08 2004-09-02 Wadih Arap Human and mouse targeting peptides identified by phage display
US7420030B2 (en) 2000-09-08 2008-09-02 The Board Of Regents Of The University Of Texas System Aminopeptidase A (APA) targeting peptides for the treatment of cancer
US8507445B2 (en) 2001-09-07 2013-08-13 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US7671010B2 (en) 2002-08-30 2010-03-02 The Board Of Regents Of The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US7598341B2 (en) * 2003-10-31 2009-10-06 Burnham Institue For Medical Research Molecules that selectively home to vasculature of premalignant or malignant lesions of the pancreas and other organs
WO2005065418A2 (en) * 2003-12-31 2005-07-21 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy
US8618054B2 (en) * 2004-05-05 2013-12-31 Valorisation-Rechereche Société en Commandite Interleukin-1 receptor antagonists, compositions, and methods of treatment
EP1924595A2 (en) * 2005-08-12 2008-05-28 Cartela R & D AB Novel peptides and uses thereof
US8664177B2 (en) 2011-02-11 2014-03-04 The Regents Of The University Of Michigan Peptide compositions and methods for treating patients
EP3246043A4 (en) * 2014-11-03 2018-09-05 Tsinghua University Drug for inhibiting adipose cell differentiation and insulin resistance
CN114272390B (en) * 2021-12-29 2022-09-02 中山大学附属第一医院 Microenvironment targeted combined cell targeted tumor inhibition carrier and preparation method and application thereof
CN114469891B (en) * 2021-12-29 2023-01-24 中山大学附属第一医院 Micromolecule drug/therapeutic gene combined delivery system with enzyme sensitive shell and preparation method and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19605175A1 (en) * 1996-02-13 1997-08-14 Sourovoi Andrej Dr Lipid compounds and their use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6030613A (en) * 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US5622699A (en) * 1995-09-11 1997-04-22 La Jolla Cancer Research Foundation Method of identifying molecules that home to a selected organ in vivo
IL131655A0 (en) * 1997-03-04 2001-01-28 Bio Technology General Corp Isolation of tissue specific ligands and their use for targeting pharmaceuticals to organs
FR2797689B1 (en) * 1999-08-16 2003-06-27 Pasteur Sanofi Diagnostics USE OF SYNTHETIC COMPOUNDS FOR IMMUNODAYS
GB9929471D0 (en) * 1999-12-13 2000-02-09 Proteom Ltd Complementary peptide ligande generated from higher eukaryote genome sequences
WO2001053342A1 (en) * 2000-01-21 2001-07-26 The Burnham Institute Chimeric prostate-homing peptides with pro-apoptotic activity
AU2001290662A1 (en) * 2000-09-08 2002-03-22 Board Of Regents, The University Of Texas System Compositions and methods for targeting peptides in humans in vivo

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19605175A1 (en) * 1996-02-13 1997-08-14 Sourovoi Andrej Dr Lipid compounds and their use

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CAMPFIEL A.L. ET AL: "Strategies and Potential Molecular Targets for Obesity Treatment", SCIENCE, vol. 280, May 1998 (1998-05-01), pages 1383 - 1387, XP002977798 *
CAMPFIELD A.L. ET AL: "Overview: neurobiology of OB protein (leptin)", PROC. NUTR. SOC., vol. 57, no. 3, August 1998 (1998-08-01), pages 429 - 440, XP002981914 *
KAHLER A. ET AL: "Chronic administration of OB protein decreases food intake by selectively meal size in male rats", AM. J. PHYSIOL., vol. 275, July 1998 (1998-07-01), pages R180 - R185, XP002981904 *
NELSON J.: "Patenting of therapeutics for obesity and nutritional disease", EXP. OPIN. THER. PATENTS, vol. 9, no. 9, 1999, pages 1185 - 1196, XP002977799 *
PASQUALINI R. ET AL: "Organ targeting in vivo using display peptide libraries", NATURE, vol. 380, March 1996 (1996-03-01), pages 364 - 366, XP002910196 *
See also references of EP1497314A4 *

Also Published As

Publication number Publication date
EP1497314A4 (en) 2007-10-10
CA2458047A1 (en) 2003-03-20
AU2002323543A1 (en) 2003-03-24
EP1497314A2 (en) 2005-01-19
WO2003022991A2 (en) 2003-03-20

Similar Documents

Publication Publication Date Title
WO2003022991A3 (en) Compositions and methods of use of targeting peptides against placenta and adipose tissues
MXPA05010830A (en) Methods of treatment of inflammatory diseases using specific binding agents of human angiopoietin-2.
GEP20166454B (en) Sclerostin binding agents
NZ500253A (en) Osteoprotegerin binding proteins and receptors
MX364100B (en) Tissue protective peptides and uses thereof.
WO2002029059A3 (en) Nogo receptor homologs
DK1005540T3 (en) IKK-beta proteins, nucleic acids and methods
WO2006113681A3 (en) Plant-derived elastin binding protein ligands and methods of using the same
MXPA03003902A (en) Prokineticin polypeptides, related compositions and methods.
YU18903A (en) Fusion protein from antibody cytokine-cytokine inhibitor (selectokine) for use as target-specific prodrug
WO2002018620A3 (en) Neutrokine-alpha and neutrokine-alpha splice variant
WO2003033658A3 (en) Neutrokine-alpha and neutrokine-alpha splice variant
MXPA02008239A (en) Human schizophrenia gene.
WO2005087811A3 (en) Estrogen receptors and methods of use
WO2002034934A3 (en) Stresscopins and their uses
DK0948536T3 (en) G protein coupled receptor with an enlarged extracellular domain
AU2003288810A1 (en) Peptides that bind to the heparin binding domian of vegf and vegfr-2
DE59809283D1 (en) INHIBITORS FOR THE UROKINAS RECEPTOR
EA200600561A1 (en) PHARMACEUTICAL PREPARATION FOR TREATMENT OF SHOCK
HK1116198A1 (en) Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
RS20060023A (en) Use of soluble cd164 in inflammatory and/or autoimmune disorders
WO2001098355A3 (en) Cgi-69 compositions and methods of use
EP1796707A4 (en) Peptides that selectively home to heart vasculature and related conjugates and methods
SE9903950D0 (en) Non-anaphylactic forms of grass pollen allergen and their use
WO2001058921A3 (en) Methods and compositions for generating angiostatin

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2458047

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 10784537

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2002757531

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006094672

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10489071

Country of ref document: US

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2002757531

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10489071

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP